Giornale italiano di cardiologia最新文献

[The ETNA-AF Europe registry: 4-year data of edoxaban use in atrial fibrillation in the Italian real world compared to the European cohort]. [欧洲 ETNA-AF 登记：意大利心房颤动患者使用埃多沙班的 4 年数据与欧洲队列对比]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-11-01 DOI: 10.1714/0000.43289

Letizia Riva, Giuseppe Andò, Maurizio Anselmi, Roberto Cemin, Daniele Nassiacos, Giovanni Fionda, Raffaele De Caterina

{"title":"[The ETNA-AF Europe registry: 4-year data of edoxaban use in atrial fibrillation in the Italian real world compared to the European cohort].","authors":"Letizia Riva, Giuseppe Andò, Maurizio Anselmi, Roberto Cemin, Daniele Nassiacos, Giovanni Fionda, Raffaele De Caterina","doi":"10.1714/0000.43289","DOIUrl":"10.1714/0000.43289","url":null,"abstract":"Background: The prospective, single-arm, observational, phase 4 ETNA-AF Europe study collected real-world data about safety, effectiveness and therapeutic adherence in European patients with non-valvular atrial fibrillation newly prescribed with edoxaban and followed up for 4 years.Methods: Overall, 13 164 patients were included in the full-analysis set, which means that they had at least one documentation after baseline at 4 years. The current paper reports about the 3329 Italian patients out of the whole European population.Results: In the Italian cohort, median age was 76.0 (69.0-82.0) years, with 57.4% of the patients being ≥75 years old. The CHA2DS2-VASc score was >4 in 586 (18.1%) patients. At baseline, 670 (20.8%) patients were classified as frail by the investigators. Edoxaban 30 mg/day was prescribed to 1013 (31.8%) patients: these were older, with more comorbidities and a lower estimated creatinine clearance compared with those receiving 60 mg/day. All-cause mortality was 4.1%/year and there were very low yearly rates of bleeding and thromboembolic events: major bleeding, 0.9%; intracranial hemorrhage, 0.2%; ischemic stroke, 0.3%; systemic embolism, <0.1%. These events were more frequent in patients ≥75 years or in patients with renal impairment or treated with edoxaban 30 mg/day. Advancing age was not associated with an increased incidence of intracranial bleeding.Conclusions: These findings confirm the favorable long-term safety and effectiveness profile of edoxaban in non-valvular atrial fibrillation patients treated in routine clinical care in Italy.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 11","pages":"819-832"},"PeriodicalIF":0.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[2024 ESC Guidelines for the management of elevated blood pressure and hypertension]. [2024年ESC血压升高和高血压管理指南]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-11-01 DOI: 10.1714/4361.43518

John William McEvoy, Cian P McCarthy, Rosa Maria Bruno, Sofie Brouwers, Michelle D Canavan, Claudio Ceconi, Ruxandra Maria Christodorescu, Stella S Daskalopoulou, Charles J Ferro, Eva Gerdts, Henner Hanssen, Julie Harris, Lucas Lauder, Richard J McManus, Gerard J Molloy, Kazem Rahimi, Vera Regitz-Zagrosek, Gian Paolo Rossi, Else Charlotte Sandset, Bart Scheenaerts, Jan A Staessen, Izabella Uchmanowicz, Maurizio Volterrani, Rhian M Touyz

引用次数: 0

[Diagnosis of arrhythmogenic cardiomyopathy: 20 years of progress and innovation]. [心律失常性心肌病的诊断：20 年的进步与创新]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43216

Domenico Corrado, Alessandro Zorzi, Barbara Bauce, Ilaria Rigato, Alberto Cipriani, Martina Perazzolo Marra, Kalliopi Pilichou, Cristina Basso, Simone Ungaro, Francesca Graziano

{"title":"[Diagnosis of arrhythmogenic cardiomyopathy: 20 years of progress and innovation].","authors":"Domenico Corrado, Alessandro Zorzi, Barbara Bauce, Ilaria Rigato, Alberto Cipriani, Martina Perazzolo Marra, Kalliopi Pilichou, Cristina Basso, Simone Ungaro, Francesca Graziano","doi":"10.1714/4336.43216","DOIUrl":"https://doi.org/10.1714/4336.43216","url":null,"abstract":"Arrhythmogenic cardiomyopathy (CMA) is a cardiac disease characterized by non-ischemic ventricular scarring and electrical instability. The diagnosis of CMA still remains challenging today and requires the use of a set of criteria, since no single diagnostic test represents the gold standard. The first diagnostic criteria were defined and disseminated in 1994 and then revised in 2010, focusing mainly on right ventricular involvement. In 2019, an international panel of experts identified the limitations of the previous diagnostic criteria. The 2020 Padua criteria included a specific pathway for the diagnosis of left ventricular variants and emphasized the need for the use of cardiac magnetic resonance imaging in the characterization of myocardial scarring. These criteria were further refined and published in 2023 as European Task Force (TF) criteria, thus gaining international recognition.Exploring the history of CMA and its diagnosis, in this review we analyze the changes and progress in the 20 years that have occurred from the first version of the criteria in 1994 to the latest in European TF of 2023, highlighting the evolution of our knowledge of the pathobiology and morpho-functional characteristics of the disease. One of the most relevant updates is undoubtedly the introduction of the concept of \"scarring/arrhythmogenic cardiomyopathy\", a definition that enhances the main features of the pathology and emphasizes the multiplicity of phenotypes and clinical presentations independent of etiology.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 10","pages":"735-746"},"PeriodicalIF":0.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Successful percutaneous treatment of complex heart disease in a stage IV non-small cell lung cancer survivor]. [成功经皮治疗一名 IV 期非小细胞肺癌幸存者的复杂心脏病]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43217

Davide Bosi, Pierluigi Demola, Giulia Alberti, Sergio Musto D'Amore, Mario Larocca, Vincenzo Guiducci, Carmine Pinto, Alessandro Navazio, Luigi Tarantini

{"title":"[Successful percutaneous treatment of complex heart disease in a stage IV non-small cell lung cancer survivor].","authors":"Davide Bosi, Pierluigi Demola, Giulia Alberti, Sergio Musto D'Amore, Mario Larocca, Vincenzo Guiducci, Carmine Pinto, Alessandro Navazio, Luigi Tarantini","doi":"10.1714/4336.43217","DOIUrl":"https://doi.org/10.1714/4336.43217","url":null,"abstract":"The presence of metastatic cancer represents a high-risk condition for the treatment of heart disease requiring surgical or percutaneous procedures. We present the case of a 58-year-old man with pulmonary adenocarcinoma and renal metastases surviving more than 3 years after chemotherapy and immunotherapy suffering dyspnea and chest pain on minimal exertion due to 99% anterior coronary artery stenosis associated with severe aortic stenosis of a bicuspid valve. We treated the cardiac lesions in two steps by coronary angioplasty with drug-eluting stent implantation followed by percutaneous prosthetic aortic valve replacement. The procedures were successful with resolution of the symptoms and recovery of the usual ECOG-PS 0-1 functional capacity which persists 24 months after cardiac procedures. This case demonstrates that the multidisciplinary collaboration between oncologists and cardiologists with a personalized patient-centered approach allows to treat complex clinical situations successfully in the emerging category of patients surviving with metastatic cancer.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 10","pages":"747-751"},"PeriodicalIF":0.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ten questions about infective endocarditis]. [关于感染性心内膜炎的十个问题]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43212

Federico Fortuni, Giuseppe Ciliberti, Nina Ajmone Marsan, Victoria Delgado, Luca Franchin, Michele Magnesa, Antonella Spinelli, Enrica Vitale, Stefano Cangemi, Stefano Cornara, Domenico Gabrielli, Furio Colivicchi, Massimo Grimaldi, Fabrizio Oliva

引用次数: 0

[Last thing on my mind: cardiac metastases]. [我最后想到的是：心脏转移]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43222

Marco Giardino, Elisabetta Tonet

引用次数: 0

[Atherosclerosis, cancer and immune checkpoint inhibitors]. [动脉粥样硬化、癌症和免疫检查点抑制剂]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43213

Maria Laura Canale, Alessandra Greco, Alessandro Inno, Andrea Tedeschi, Marzia De Biasio, Stefano Oliva, Irma Bisceglia, Nicola Maurea, Luigi Tarantini, Giuseppina Gallucci, Michele Massimo Gulizia, Fabio Maria Turazza, Fabiana Lucà, Stefania Angela Di Fusco, Carmine Riccio, Alessandro Navazio, Leonardo De Luca, Domenico Gabrielli, Furio Colivicchi, Massimo Grimaldi, Fabrizio Oliva

{"title":"[Atherosclerosis, cancer and immune checkpoint inhibitors].","authors":"Maria Laura Canale, Alessandra Greco, Alessandro Inno, Andrea Tedeschi, Marzia De Biasio, Stefano Oliva, Irma Bisceglia, Nicola Maurea, Luigi Tarantini, Giuseppina Gallucci, Michele Massimo Gulizia, Fabio Maria Turazza, Fabiana Lucà, Stefania Angela Di Fusco, Carmine Riccio, Alessandro Navazio, Leonardo De Luca, Domenico Gabrielli, Furio Colivicchi, Massimo Grimaldi, Fabrizio Oliva","doi":"10.1714/4336.43213","DOIUrl":"10.1714/4336.43213","url":null,"abstract":"Immunotherapy has revolutionized the treatment of various cancers leading to a clear survival benefit with cured or long-surviving patients. Atherosclerosis and cancer share risk factors and molecular mechanisms and have as their common thread a state of chronic inflammation linked to a deregulation of the immune system. A growing body of evidence is accumulating on the potential worsening effect of immune checkpoint inhibitors on atherosclerosis, with subsequent worsening of patients' long-term cardiovascular risk. The molecular pathways implicated in the growth and deregulation of atherosclerotic plaques seem to be the same (CTLA-4, PD-1, PD-L1) as those on which the anti-tumor effect is exerted. Owing to the increasing number of cancer patients treated with immunotherapy and the improved survival with the possibility of prolonged disease control, it is necessary to know the potential increase in cardiovascular risk for atherosclerosis-related events and to establish all prevention measures to reduce it.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 10","pages":"711-719"},"PeriodicalIF":0.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Hematologic malignancies and increased cardiovascular risk: a new issue to be considered for patient follow-up]. [血液恶性肿瘤与心血管风险增加：患者随访中需要考虑的新问题]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43214

Vincenzo Toschi, Maddalena Lettino

{"title":"[Hematologic malignancies and increased cardiovascular risk: a new issue to be considered for patient follow-up].","authors":"Vincenzo Toschi, Maddalena Lettino","doi":"10.1714/4336.43214","DOIUrl":"10.1714/4336.43214","url":null,"abstract":"The last decade has seen a significant increase in the number of long survivors after a hematologic cancer, both children and adults, due to significant improvement in treatment. This exciting result, however, has been associated with an increase in the occurrence of previously unknown cardiovascular complications, including acute myocardial infarction, stroke, heart failure, deep vein thrombosis and pulmonary embolism. These adverse outcomes are due to both the hematologic cancer per se and to antineoplastic therapy. Cancer-dependent complications are caused by a shift of blood and endothelial cells to a prothrombotic and proinflammatory phenotype associated also with cancer-related somatic gene mutations. Antineoplastic therapy, instead, can lead to adverse outcomes due to an increase in oxidative stress resulting from the effects of reactive oxygen and nitrogen species which can induce alterations of mitochondria and other intracellular organelles. In addition, cardiovascular complications following a hematologic malignancy are also due to the interaction between cancer and traditional cardiovascular risk factors such as smoking, hypertension, obesity and diabetes. Clinicians should take all of these factors into account, and adapt their usual follow-up schemes accordingly in patients who have survived a hematologic cancer.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 10","pages":"720-727"},"PeriodicalIF":0.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Secondary prevention in patients with transient ischemic attack or stroke due to carotid atherosclerosis]. [颈动脉粥样硬化引起的短暂性脑缺血发作或中风患者的二级预防]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43215

Maurizio Paciaroni

引用次数: 0

[ECG, pain, and the importance of details]. [心电图、疼痛和细节的重要性]。

IF 0.7

Giornale italiano di cardiologia Pub Date : 2024-10-01 DOI: 10.1714/4336.43211

Giulio Falasconi, Massimo Slavich

引用次数: 0